News – Page 1025 – Endpoints News

Faster, cheaper DNA sequencing gets Omniome $60M led by Chinese investors

7 years ago

Top 10: Takeda's late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?

7 years ago

Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup

7 years ago

Fresh out of 6 Dimensions' incubator, Curon launches with $150M and backing from Boyu, Temasek

7 years ago

Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML

7 years ago

Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for ...

7 years ago

FDA approves cancer radiation drug Azedra, sending Progenics stock north

7 years ago

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope

7 years ago

We've scheduled your Type T meeting with FDA commish Scott Gottlieb, where you can learn the art of rapid fire R&D

7 years ago

As it fights looming competition on Suboxone, Indivior gets FDA OK on new schizophrenia drug

7 years ago

Sienna concedes failure in pivotal acne trial — will the laser-managed therapy work in hair reduction?

7 years ago

Would AbbVie’s top execs really pull the trigger on a $30B M&A deal? Why, yes, actually

7 years ago

FDA outlines a laundry list of surrogate endpoints with an eye to expanding the roster for drug developers

7 years ago

Big Pharma analyst Tim Anderson drops off the radar at Bernstein, headed to a new research home

7 years ago

Kickback, bribery and racketeering charges are followed by a CRL for opioid spray at scandal-plagued Insys

7 years ago

After huge mega-round, CStone poaches Goldman's Richard Yeh as CFO; Both Hooper and Harper exit Amgen's revolving ...

7 years ago

In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO

7 years ago

Tonix crashes on PhIII PTSD failure, sending stock to the gutter

7 years ago

FDA finalizes guidance closing pediatric study loophole

7 years ago

CHMP recommends OK for Alnylam's patisiran; Amgen scraps a BCMA ADC

7 years ago

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market

7 years ago

Bristol-Myers takes another hit on Opdivo/Yervoy combo as CHMP turns thumbs down on frontline kidney cancer

7 years ago

Antibiotics R&D takes another hit as Achaogen slashes research ops in reorganization

7 years ago

Amgen R&D chief Sean Harper hits the exits with a one-way ticket to early-stage biotech

7 years ago

First page Previous page 1022 1023 102410251026 1027 1028 Next page Last page